Endometriosis has long been a case study in how women’s pain is sidelined, with patients often waiting close to a decade for a definitive answer while symptoms chip away at their work, relationships, and fertility. Now a wave of diagnostics startups, backed by new biomarker science and menstrual blood testing, are promising to compress that journey from years of uncertainty to something closer to a standard lab workup. I see a field that is finally treating early, noninvasive diagnosis as a solvable problem rather than an inevitable ordeal.
The stakes are enormous. The World Health Organization estimates that about 10% of women and girls of reproductive age worldwide live with endometriosis, yet many are still told their pain is “normal” or “in their head” until damage is already done. The new tools arriving in clinics and clinical trials are not just gadgets, they are a direct response to that history of dismissal and delay.
Why diagnosis still takes years
The core reason endometriosis is diagnosed so slowly is structural: the current gold standard is laparoscopic surgery, which requires an operating room, anesthesia, and a surgeon skilled enough to spot subtle lesions. That bar means many patients are left in limbo on painkillers or hormonal therapies while they wait for a specialist who can offer laparoscopy, even though the procedure itself is invasive, costly, and not without risk, as highlighted in descriptions of the gold standard. In practice, that means diagnosis is often reserved for those whose symptoms are severe enough to justify surgery, not those at the earliest stages when intervention could prevent long term damage.
Clinicians who treat endometriosis describe an average diagnostic delay that stretches across much of a patient’s twenties, with people seeing multiple providers before anyone connects the dots. In one televised interview, Dr. Homewood walked through how patients are bounced between primary care, emergency rooms, and gynecology, often being told heavy periods are simply part of life. That pattern is echoed in advocacy campaigns like a recent Women’s Health Research Day post that described how “Current diagnosis relies on invasive laparoscopy” and framed the status quo as a call to action for more funding and a system that actually believes patients, a message amplified in an Instagram explainer.
The Big Shift away from surgical “gold standard”
What is changing now is a growing consensus that relying on surgery as the primary diagnostic gatekeeper is no longer defensible. One fertility specialist described “The Big Shift” in endometriosis care as recognizing that laparoscopy is “NO LONGER the ‘Gold Standard’” for diagnosis, arguing that the future lies in something “much simpler, faster, and non invasive” that can be deployed earlier in the care pathway, a view laid out in a detailed analysis. I see that shift not as a rejection of surgery altogether, but as a reclassification of laparoscopy into what it arguably should have been all along, a therapeutic tool and a confirmatory option for complex cases rather than the first and only way to get a name for the disease.
Regulators and funders are starting to align with that thinking by backing noninvasive approaches that can be used in primary care or fertility clinics. During Endometriosis Action Month, one review of innovation efforts noted that “Whilst we wait for the winners to be announced in March 2026,” a range of companies and researchers are already building systems for characterising the “menstrualome,” the molecular fingerprint of menstrual blood, as part of a broader push to move diagnosis out of the operating room and into the lab, a trend captured in a survey of advances. That reorientation is what gives startups room to argue that a 10 day test could one day replace an 11 year wait.
Blood based diagnostics move into clinics
One of the most tangible signs of progress is the arrival of blood tests that are already being offered to patients. Kephera Diagnostics, a CLIA certified and CAP accredited laboratory based in Framingham, has launched EndomTest, described as a laboratory developed test intended to aid in the differential diagnosis of endometriosis, according to company materials and a detailed announcement. A separate report on the same launch emphasized that Kephera Diagnostics, described again as CLIA certified and CAP accredited, sees the test as having the potential to transform patient care by giving clinicians a new tool to evaluate people with chronic pelvic pain, a vision laid out in a clinical briefing.
Kephera’s move builds on a broader pipeline of blood based diagnostics that aim to read the molecular signatures of endometriosis rather than hunt for lesions directly. Researchers at Yale, for example, have identified novel biomarkers that could allow doctors to detect endometriosis in its earliest stages through a simple blood draw, before the disease causes irreversible damage, according to a summary of work by Researchers. That science helped seed the patent portfolio of DotLab, whose DotEndo test is described as “Advanced” and “Non” invasive, working by measuring biomarkers in the blood and applying biostatistics to identify endometriosis, according to the company’s overview.
Menstrual blood and stem cells rewrite the playbook
While blood tests are gaining traction, some of the most radical work is happening in menstrual blood itself. Scientists have developed an approach that uses readily available menstrual blood samples to accurately diagnose and categorise endometriosis, avoiding the need for an invasive tissue biopsy called laparoscopy, as described in a report on how Scientists are rethinking diagnostics. A related account in Hospital Times explained that this method can also shed light on the mechanisms that drive lesion formation, turning a diagnostic sample into a research tool, a dual role highlighted in the same approach.
Other teams are pushing sensitivity even further. Pan and his group have developed a proof of concept device capable of detecting HMGB1, a protein implicated in endometriosis development, in menstrual blood with five times greater sensitivity than existing methods, according to a technical report on work by Pan and colleagues. Another project, described as a Groundbreaking Test Uses Menstrual Blood to Diagnose Endometriosis in Minutes, suggests that such devices could compress the diagnostic timeline from years to minutes, a leap in speed that advocates say could change how seriously clinicians take early symptoms, as outlined in a profile of the Minutes long assay.
Devices, AI, and the race to commercialize
Not every startup is betting on fluids. EndoCure, a medical device company, is building a proprietary robotic ultrasound imaging platform called Revealan that aims to redefine diagnosis by improving visualization of endometriosis lesions and speeding up market adoption of noninvasive imaging, according to a profile of Revealan. EndoDiagnosis Inc, meanwhile, is rolling out the ENDOSURE device, described as a way to speed up diagnosis with unmatched precision and prevent long term health problems by catching disease earlier, as detailed in a release on the ENDOSURE system. A separate announcement noted that CReATe Fertility in Canada has become the first clinic in that country to offer a Tier 1 Endosure diagnostic test, underscoring how quickly such devices can spread once a clinic proves they fit into real world workflows, a milestone flagged in the description of Endosure.
On the software side, Heranova Lifesciences is positioning its product, called HerResolve, as a way to “Replace Surgery” with “Its Endometriosis Diagnostic,” aiming to reserve surgical intervention only for therapeutic purposes, according to a feature on how How One Startup to change care. The same report, introduced under “Share Options,” noted that The World Health Organization’s estimate that about 10% of women and girls of reproductive age are affected is a key part of the company’s pitch that the market is both huge and underserved, a framing that appears in the Share Options section. Behind the scenes, femtech patent analyses point out that many of these tools rely on measuring protein expression levels using methods like ELISA, mass spectrometry, and protein arrays, techniques that are helping build robust biomarker panels and contributing data for research, as catalogued in a review of ELISA based platforms.
More from Morning Overview